Partnerships

Encycle Therapeutics announces discovery collaboration with Pfizer Inc.

TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a research collaboration with Pfizer Inc. (“Pfizer”) (NYSE: PFE). Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s proprietary nacellin library, that act on an undisclosed therapeutic target. Nacellins are a type of peptide macrocycle that can often exhibit ... Read more

LAB150 – Strategic Partnership with Evotec AG

Toronto, Sept. 14, 2017 (GLOBE NEWSWIRE) -- MaRS Innovation (“MI”) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the launch of “LAB150”.  This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation. A crucial lack of the funding, specialized infrastructure and drug development expertise necessary to translate disease-related biological pathways into focused drug ... Read more

MaRS Innovation and KHIDI commence joint research initiatives

TORONTO, ON--(Marketwired - April 18, 2017) - MaRS Innovation (MI) and its South Korean partner, Korea Health Industry Development Institute (KHIDI), continue to build on the five-year global partnership agreement signed in December 2016 during Premier Wynne's mission to the Republic of Korea. Together with Minister Moridi, Ontario Minister of Research, Innovation and Science, Rafi Hofstein, CEO of MI, is in Seoul to further the joint research initiatives first envisaged last year. Five outstanding Ontario scientists from some of MI's Member institutions are ... Read more

Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics

Toronto, Canada and Hamburg, Germany, 17 January 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP (“Fibrocor”), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. The company was launched with CDN $ 2.8 m (approx. $ 2.1 m) financing, which includes cash from MaRS Innovation. Evotec will provide all drug discovery activities and will also receive an equity stake. Fibrocor takes a new approach to understanding and ... Read more

MaRS Innovation and KHIDI, South Korea, Creates $100M Global Commercialization Partnership

Today MaRS Innovation (MI) and the Korea Health Industry Development Institute (KHIDI) signed a five year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations which is expected to generate new startups worth over $100M. This agreement will promote the co-development and commercialization of medical technologies and therapeutics between Ontario and South Korea in concert with industry and government. It will provide the resources to develop and implement novel technological solutions for today’s most urgent healthcare problems and ... Read more

Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia

VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI). This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ... Read more

MaRS Innovation highlighted in the ExcelleNCE newsletter

MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses the success of the MaRS Innovation commercialization model. The article mentions companies such as ScarX Therapeutics, a spin-off of MI and Toronto’s Hospital for Sick Children that is commercializing a topical prescription cream. It also talks about Encycle Therapeutics, a Toronto biotechnology start-up from the University of Toronto, that has developed a fast, ... Read more

Dr. Raphael Hofstein in Biotechnology Focus: Canada’s Contagiously Creative Life Sciences Sector

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published the following guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications. There’s a historical trend in Canadian culture with far-reaching effects for the way we do business, ranging from entertainment to academia to science. Namely, it’s that until quite recently, Canadians weren’t into cultivating national star systems. [1] As Gideon Hayden recently wrote for TechCrunch, if you’re a Canadian tall poppy ... Read more

Israel’s BioLineRx and Canada’s MaRS Innovation sign framework collaboration agreement

Agreement signed as part of Ontario's life sciences trade mission to Israel TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation,  the commercialization agent for 15 of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ... Read more

Johnson & Johnson Innovation Opens JLABS @ Toronto

TORONTO (May 11, 2016) –  Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ... Read more
Page 1 of 1412345...10...Last »